Tag Archive | "royalty financing"

Vertex in $3.3 billion royalty financing with Royalty Pharma

Tags: , ,


Royalty Pharma announced its acquisition of royalties on Vertex Pharmaceuticals’ cystic fibrosis treatments owned by Cystic Fibrosis Foundation Therapeutics Read the full story

Rush University Medical Center receives $42 million in royalty financing

Tags: , ,


DRI Capital and Rush University Medical Center announced that Drug Royalty III, DRI has purchased Rush’s royalties relating to worldwide sales of Ampyra for approximately $42 million. Read the full story

Supernus pharma raises $30 million by royalty financing

Tags: , ,


Supernus Pharmaceuticals announced the execution of a royalty financing agreement with HealthCare Royalty Partners. Read the full story

Synthetic royalty

Tags:


A royalty created where none had previously existed. The royalty stream is generated from future sales ... Read the full story

Royalty financing

Tags:


A sale of rights to royalties for sale of the product which would have otherwise been due to the licensor... Read the full story

Industry trend analysis: royalty and revenue financing deals

Tags: , ,


This article talks about the industry trend analysis of signing royalty and revenue financing deals among life science sectors Read the full story

Royalty Pharma receives $510 million in royalty financing

Tags: , ,


Royalty Pharma has acquired an additional interest in the royalty financing to the former shareholders of Fumapharm AG for $510 million in cash. Read the full story

Vertex ends its pharma deal with Janssen

Tags: , , , ,


Vertex brings a long time pharma deal with Janssen to an end by sell its royalty rights on INCIVO net sales.  Read the full story

DRI Capital in $1.45 billion equity financing round

Tags: , ,


DRI Capital announced the final closing of its U.S. $1.45 billion Drug Royalty III private equity financing fund. Read the full story

Royalty Pharma sells $485 million interest to Aisling Capital and Clarus Ventures in royalty financing round

Tags: , , ,


Royalty Pharma has sold it's $485 million interest in Ibrutinib to Aisling Capital and Clarus Ventures in a royalty financing round. Read the full story